Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.

Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y.

J Clin Oncol. 2019 Jun 4:JCO1900320. doi: 10.1200/JCO.19.00320. [Epub ahead of print]

PMID:
31163011
2.

Prognostic Significance of "Nonsolid" Microscopic Metastasis in Merkel Cell Carcinoma Sentinel Lymph Nodes.

Erstine EM, Tetzlaff MT, Jia X, Aung PP, Prieto VG, Funchain P, Gastman BR, Billings SD, Ko JS.

Am J Surg Pathol. 2019 Jul;43(7):907-919. doi: 10.1097/PAS.0000000000001277.

PMID:
31094923
3.

The Microbiome of Temporal Arteries.

Hoffman GS, Getz TM, Padmanabhan R, Villa-Forte A, Clifford AH, Funchain P, Sankunny M, Perry JD, Blandford A, Kosmorsky G, Lystad L, Calabrese LH, Eng C.

Pathog Immun. 2019 Feb 12;4(1):21-38. doi: 10.20411/pai.v4i1.270. eCollection 2019.

4.

Sentinel lymph node biopsy in Merkel cell carcinoma: Predictors of sentinel lymph node positivity and association with overall survival.

Conic RR, Ko J, Saridakis S, Damiani G, Funchain P, Vidimos A, Gastman BR.

J Am Acad Dermatol. 2019 Mar 19. pii: S0190-9622(19)30441-4. doi: 10.1016/j.jaad.2019.03.027. [Epub ahead of print]

PMID:
30902726
5.

Immune Check Point Inhibitor-Associated Glomerulonephritis.

Ashour T, Nakhoul G, Patil P, Funchain P, Herlitz L.

Kidney Int Rep. 2018 Oct 29;4(2):355-359. doi: 10.1016/j.ekir.2018.10.017. eCollection 2019 Feb. No abstract available.

6.

Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash.

Patil PD, Fernandez AP, Velcheti V, Tarhini A, Funchain P, Rini B, Khasawneh M, Pennell NA.

Oncologist. 2019 Jan;24(1):4-8. doi: 10.1634/theoncologist.2018-0434. Epub 2018 Oct 24.

PMID:
30355774
7.

Decreased T-Cell Programmed Death Receptor-1 Expression in Pregnancy-Associated Melanoma.

Ko JS, Gastman BR, Conic R, Tellez Diaz Trujillo A, Diaz-Montero CM, Billings SD, Tarhini A, Funchain P, Atanaskova Mesinkovska N.

Am J Dermatopathol. 2019 Mar;41(3):180-187. doi: 10.1097/DAD.0000000000001286.

PMID:
30308543
8.

Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB.

Cancer. 2019 Jan 1;125(1):18-44. doi: 10.1002/cncr.31719. Epub 2018 Oct 3. Review.

PMID:
30281145
9.

Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database.

Conic RRZ, Ko J, Damiani G, Funchain P, Knackstedt T, Vij A, Vidimos A, Gastman BR.

J Am Acad Dermatol. 2019 Feb;80(2):441-447. doi: 10.1016/j.jaad.2018.08.051. Epub 2018 Sep 18.

PMID:
30240775
10.

How should we diagnose and manage checkpoint inhibitor-associated colitis?

Khan F, Funchain P, Bennett A, Hull TL, Shen B.

Cleve Clin J Med. 2018 Sep;85(9):679-683. doi: 10.3949/ccjm.85a.18020. No abstract available.

11.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.

Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N.

Clin Cancer Res. 2018 Nov 1;24(21):5250-5260. doi: 10.1158/1078-0432.CCR-18-0309. Epub 2018 Jul 18.

PMID:
30021908
12.

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series.

Sun L, Funchain P, Song JM, Rayman P, Tannenbaum C, Ko J, Mcnamara M, Marcela Diaz-Montero C, Gastman B.

J Immunother Cancer. 2018 May 16;6(1):36. doi: 10.1186/s40425-018-0337-7.

13.

Using Genomic Sequencing to Improve Management in Melanoma.

Funchain P, Tarhini AA.

Oncology (Williston Park). 2018 Mar 15;32(3):98-101, 104.

14.

Melanoma cases demonstrate increased carrier frequency of phenylketonuria/hyperphenylalanemia mutations.

Arbesman J, Ravichandran S, Funchain P, Thompson CL.

Pigment Cell Melanoma Res. 2018 Jul;31(4):529-533. doi: 10.1111/pcmr.12695. Epub 2018 Mar 12.

PMID:
29473999
15.

Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma.

Stiegel E, Xiong D, Ya J, Funchain P, Isakov R, Gastman B, Vij A.

J Am Acad Dermatol. 2018 May;78(5):942-948. doi: 10.1016/j.jaad.2018.01.030. Epub 2018 Jan 31.

PMID:
29408526
16.

Changing Treatment Paradigms for Brain Metastases From Melanoma-Part 2: When and How to Use the New Systemic Agents.

Venur VA, Funchain P, Kotecha R, Chao ST, Ahluwalia MS.

Oncology (Williston Park). 2017 Sep 15;31(9):659-67. Review.

17.

Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance.

Barata PC, Koshkin VS, Funchain P, Sohal D, Pritchard A, Klek S, Adamowicz T, Gopalakrishnan D, Garcia J, Rini B, Grivas P.

Ann Oncol. 2017 Oct 1;28(10):2458-2463. doi: 10.1093/annonc/mdx405.

PMID:
28945843
18.

Changing Treatment Paradigms for Brain Metastases From Melanoma-Part 1: Diagnosis, Prognosis, Symptom Control, and Local Treatment.

Venur VA, Funchain P, Kotecha R, Chao ST, Ahluwalia MS.

Oncology (Williston Park). 2017 Aug 15;31(8):602-6. Review.

19.

Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.

Kotecha R, Miller JA, Venur VA, Mohammadi AM, Chao ST, Suh JH, Barnett GH, Murphy ES, Funchain P, Yu JS, Vogelbaum MA, Angelov L, Ahluwalia MS.

J Neurosurg. 2018 Jul;129(1):50-59. doi: 10.3171/2017.1.JNS162797. Epub 2017 Aug 11.

PMID:
28799876
20.

Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas.

Wang H, Funchain P, Bebek G, Altemus J, Zhang H, Niazi F, Peterson C, Lee WT, Burkey BB, Eng C.

Genome Med. 2017 Feb 7;9(1):14. doi: 10.1186/s13073-017-0405-5.

21.

Metabolomic analysis identifies differentially produced oral metabolites, including the oncometabolite 2-hydroxyglutarate, in patients with head and neck squamous cell carcinoma.

Mukherjee PK, Funchain P, Retuerto M, Jurevic RJ, Fowler N, Burkey B, Eng C, Ghannoum MA.

BBA Clin. 2016 Dec 18;7:8-15. doi: 10.1016/j.bbacli.2016.12.001. eCollection 2017 Jun.

22.

Prevalence of HPV Infection in Racial-Ethnic Subgroups of Head and Neck Cancer Patients.

Ragin C, Liu JC, Jones G, Shoyele O, Sowunmi B, Kennett R, Groen HJ, Gibbs D, Blackman E, Esan M, Brandwein MS, Devarajan K, Bussu F, Chernock R, Chien CY, Cohen MA, Samir EM, Mikio S, D'Souza G, Funchain P, Eng C, Gollin SM, Hong A, Jung YS, Krüger M, Lewis J Jr, Morbini P, Landolfo S, Rittà M, Straetmans J, Szarka K, Tachezy R, Worden FP, Nelson D, Gathere S, Taioli E.

Carcinogenesis. 2016 Dec 26. pii: bgw203. doi: 10.1093/carcin/bgw203. [Epub ahead of print]

23.

Strategies for clinical implementation of screening for hereditary cancer syndromes.

Heald B, Marquard J, Funchain P.

Semin Oncol. 2016 Oct;43(5):609-614. doi: 10.1053/j.seminoncol.2016.08.008. Epub 2016 Sep 21. Review.

PMID:
27899194
24.

Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations.

Hong S, Funchain P, Haddad A, Crowe J, Dalpiaz N, Abraham J.

J Oncol Pract. 2016 Mar;12(3):270-2. doi: 10.1200/JOP.2016.010710. No abstract available.

PMID:
26962171
25.

Prospective Clinical Study of Precision Oncology in Solid Tumors.

Sohal DP, Rini BI, Khorana AA, Dreicer R, Abraham J, Procop GW, Saunthararajah Y, Pennell NA, Stevenson JP, Pelley R, Estfan B, Shepard D, Funchain P, Elson P, Adelstein DJ, Bolwell BJ.

J Natl Cancer Inst. 2015 Nov 9;108(3). pii: djv332. doi: 10.1093/jnci/djv332.

PMID:
26553780
26.

Hunting for cancer in the microbial jungle.

Funchain P, Eng C.

Genome Med. 2013 May 29;5(5):42. doi: 10.1186/gm446. eCollection 2013. No abstract available.

27.

A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines.

Hesson LB, Packham D, Pontzer E, Funchain P, Eng C, Ward RL.

Biol Proced Online. 2012 Apr 10;14(1):5. doi: 10.1186/1480-9222-14-5.

28.

Microbiomic subprofiles and MDR1 promoter methylation in head and neck squamous cell carcinoma.

Bebek G, Bennett KL, Funchain P, Campbell R, Seth R, Scharpf J, Burkey B, Eng C.

Hum Mol Genet. 2012 Apr 1;21(7):1557-65. doi: 10.1093/hmg/ddr593. Epub 2011 Dec 15.

29.

Acute liver injury induced by weight-loss herbal supplements.

Chen GC, Ramanathan VS, Law D, Funchain P, Chen GC, French S, Shlopov B, Eysselein V, Chung D, Reicher S, Pham BV.

World J Hepatol. 2010 Nov 27;2(11):410-5. doi: 10.4254/wjh.v2.i11.410.

30.
31.

Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets.

Rush LJ, Raval A, Funchain P, Johnson AJ, Smith L, Lucas DM, Bembea M, Liu TH, Heerema NA, Rassenti L, Liyanarachchi S, Davuluri R, Byrd JC, Plass C.

Cancer Res. 2004 Apr 1;64(7):2424-33.

32.

Temporary and permanent mutators lacking the mismatch repair system: the enhancement of mutators in cell populations.

Miller JH, Yeung A, Funchain P, Mao E, Stewart J, Clendenin WM, Slupska MM.

Cold Spring Harb Symp Quant Biol. 2000;65:241-52. Review. No abstract available.

PMID:
12760038
33.

In vitro and in vivo studies of MutS, MutL and MutH mutants: correlation of mismatch repair and DNA recombination.

Junop MS, Yang W, Funchain P, Clendenin W, Miller JH.

DNA Repair (Amst). 2003 Apr 2;2(4):387-405.

PMID:
12606120
34.

Escherichia coli strains (ndk) lacking nucleoside diphosphate kinase are powerful mutators for base substitutions and frameshifts in mismatch-repair-deficient strains.

Miller JH, Funchain P, Clendenin W, Huang T, Nguyen A, Wolff E, Yeung A, Chiang JH, Garibyan L, Slupska MM, Yang H.

Genetics. 2002 Sep;162(1):5-13.

35.

Amplification of mutator cells in a population as a result of horizontal transfer.

Funchain P, Yeung A, Stewart J, Clendenin WM, Miller JH.

J Bacteriol. 2001 Jun;183(12):3737-41.

36.

Supplemental Content

Loading ...
Support Center